Immunomic Therapeutics Announces Exclusive License of Phase II Cancer Immunotherapy Technology Targeting …Business Wire (press release)This new license allows Immunomic to combine its investigational nucleic acid based immunotherapy platform, LAMP-Va… Continue reading
Korea JoongAng DailyIntellia moves closer to clinic with CRISPR techFierceBiotechIntellia Therapeutics has taken another step toward human trials of its gene editing technology, after reporting new data in animal models. The CRISPR specialist says it h… Continue reading
|
Crispr Delivers a Crisp, New Model for Chronic Granulomatous Disease
Genetic Engineering & Biotechnology News Approximately 6 million people worldwide suffer from primary inherited immunodeficiency diseases which pose a life-long challenge for those affected by them (Bousfiha et al., 2013). Chronic Granulomatous Disease (CGD) is one such illness that impairs … |
BBC News |
Stem cell transplant to tackle Huntington’s disease
BBC News People with the degenerative disorder Huntington’s disease could receive pioneering treatment with stem cells to try to slow development of symptoms. Cardiff University plans to begin the first transplants at a specialist brain centre by the end of the … |
BBC News |
Stem cell transplant to tackle Huntington’s disease
BBC News People with the degenerative disorder Huntington’s disease could receive pioneering treatment with stem cells to try to slow development of symptoms. Cardiff University plans to begin the first transplants at a specialist brain centre by the end of the … |